Photocure Partner Asieris to present first results for its Hexvix Phase III clinical trial in China at the SIU 2023 Annual Meeting
Press Release – Oslo, Norway, October 7, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated its plan today to unveil the first results of its Hexvix[®] (APL-1706) Phase III clinical trial in China.The pivotal clinical trial results have been selected as a “late-breaking abstract” for the 43rd Congress of the Société Internationale d’Urologie (SIU) in Istanbul, Turkey, this month. The clinical study results will be presented for the first time in the form of an Oral ePoster on Thursday, October 12,